Abstract
The 2025 meeting of the International Society for Magnetic Resonance in Medicine (ISMRM) included critical discussions on the role of breast magnetic resonance imaging (MRI) in cancer detection and treatment monitoring. This article reflects on key innovations presented at the meeting, particularly Abbreviated Breast MRI (AB-MRI) protocols and synthetic MRI, and examines their implications for improving access and equity in breast cancer screening. This commentary is based on publicly available ISMRM 2025 proceedings and editorial coverage. Notable presentations from Dr. Christopher Comstock and Dr. Martin Blaimer highlighted the potential of these technologies to enhance diagnostic performance, reduce scan time, and lower costs. Additional insights from sessions led by Drs. Morris, Pinker-Domenig, Partridge, and Baltzer also emphasised the importance of adopting scalable MRI solutions in population- level cancer control strategies, especially in underserved regions. This commentary also addressed broader implications for cancer surveillance and the structural challenges of integrating advanced imaging into public health frameworks. Together, these advancements represented timely opportunity to close detection gaps, improve outcomes, and support equitable, patient-centered cancer care.
Key words: Mammography, Magnetic Resonance Imaging, Public health, Radiology, Women
|